Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amg 811
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
AMG 811 is a fully human IgG1 monoclonal antibody developed by Amgen that selectively targets and neutralizes human interferon gamma (IFN-γ). Its mechanism of action involves binding to IFN-γ and inhibiting its activity, thereby modulating downstream immune responses associated with autoimmune diseases. AMG 811 was investigated primarily for the treatment of systemic lupus erythematosus (SLE), including lupus nephritis, discoid lupus erythematosus (DLE), and psoriasis. Clinical studies demonstrated that while AMG 811 effectively reduced IFN-γ-associated biomarkers such as CXCL10 protein levels and gene expression signatures in blood and skin, it did not show significant clinical efficacy in improving disease outcomes. The drug exhibited an acceptable safety profile but development has been discontinued for these indications[1][2][3][5][7].
- Other names
- Anti-IFN-gamma mAb
02
Targets
IFNG (Interferon gamma)
Beyond the preview
Go deeper on amg 811.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amg 811.